Jim Clemmer, CEO of AngioDynamics, shares how he transformed the company into a science-driven innovator focused on cancer and cardiovascular disease through bold portfolio changes, deep physician engagement, and a strong market access strategy. His insights highlight the importance of agility, data-driven credibility, and aligning reimbursement early to bring groundbreaking MedTech technologies to market.
Chad Andresen (Sat,) studied this question.